Melatonin Administration from 2000 to 2020 to Human Newborns with Hypoxic-Ischemic Encephalopathy

Area of Science:

• Neonatal neurology
• Pediatric critical care
• Pharmacology

Background:

• Hypoxic-ischemic encephalopathy (HIE) is a leading cause of long-term neurodevelopmental disability in term infants globally.
• Melatonin, a hormone with demonstrated antioxidant and anti-inflammatory properties, is being investigated for its therapeutic potential in perinatal asphyxia.
• The combination of hypothermia and melatonin may offer synergistic neuroprotective effects for infants with HIE.

Purpose of the Study:

• To review the existing research on the neuroprotective effects of melatonin in infants with HIE.
• To summarize the advantages and limitations of studies investigating melatonin for HIE treatment.
• To highlight the need for larger clinical trials in newborns.

Main Methods:

• Literature review of studies on melatonin's efficacy in reducing oxidative stress.
• Analysis of animal studies demonstrating melatonin's neuroprotective capabilities.
• Examination of available clinical data, acknowledging the lack of large-scale newborn trials.

Main Results:

• Animal studies consistently show melatonin's efficacy in reducing oxidative stress.
• Clinical evidence in newborns is limited, with a lack of large-scale trials to confirm efficacy and safety.
• The synergistic potential of melatonin with hypothermia warrants further investigation.

Conclusions:

• Melatonin is a promising therapeutic agent for HIE due to its antioxidant and anti-inflammatory actions.
• Further well-designed, large-scale clinical trials in newborns are essential to establish melatonin's role in HIE management.
• Combining melatonin with hypothermia may enhance neuroprotection in infants suffering from perinatal asphyxia.